3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Anus Neoplasms
1
Anal Canal Carcinoma
1
Interventions
pembrolizumab
33
Paclitaxel
27
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Fulvestrant
15
fludarabine
14
Trastuzumab
14
aldesleukin
13
Docetaxel
13
Early Intervention, Educational
12
Surveys and Questionnaires
11
veliparib
10
palbociclib
10
Methods
10
Gemcitabine
10
Blood Specimen Collection
10
Nivolumab
9
Flow Cytometry
9
Biopsy
9
Bevacizumab
9
sargramostim
8
niraparib
7
liposomal doxorubicin
7
Therapeutics
7
Taxes
7
Standard of Care
7
Psychiatric Rehabilitation
7
Magnetic Resonance Spectroscopy
7
talazoparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
rocakinogene sifuplasmid
×
Gynecologic
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled